Merit Medical Systems Inc
$ 70.93
1.18%
17 Apr - close price
- Market Cap 4,230,853,000 USD
- Current Price $ 70.93
- High / Low $ 71.91 / 70.33
- Stock P/E 33.30
- Book Value 26.66
- EPS 2.13
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.09 %
- 52 Week High 100.19
- 52 Week Low 66.34
About
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, intensive care, and endoscopy. The company is headquartered in South Jordan, Utah.
Analyst Target Price
$99.45
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-10-30 | 2025-07-30 | 2025-04-28 | 2025-02-26 | 2024-10-30 | 2024-08-01 | 2024-04-30 | 2024-02-28 | 2023-10-26 | 2023-07-25 | 2023-04-26 |
| Reported EPS | 1.04 | 0.92 | 1.01 | 0.86 | 0.93 | 0.86 | 0.92 | 0.77 | 0.81 | 0.75 | 0.81 | 0.64 |
| Estimated EPS | 0.9498 | 0.83 | 0.8475 | 0.7493 | 0.83 | 0.8 | 0.87 | 0.71 | 0.77 | 0.65 | 0.75 | 0.55 |
| Surprise | 0.0902 | 0.09 | 0.1625 | 0.1107 | 0.1 | 0.06 | 0.05 | 0.06 | 0.04 | 0.1 | 0.06 | 0.09 |
| Surprise Percentage | 9.4967% | 10.8434% | 19.174% | 14.7738% | 12.0482% | 7.5% | 5.7471% | 8.4507% | 5.1948% | 15.3846% | 8% | 16.3636% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.73 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MMSI
2026-04-18 22:35:31
Merit Medical Systems has completed the acquisition of View Point Medical, Inc. for approximately $140 million. This merger, finalized on April 1, 2026, involves an initial $90 million cash payment and two subsequent deferred payments of $25 million each. The acquisition aims to enhance Merit's minimally invasive diagnostic and oncology portfolio with View Point Medical's tumor localization technology.
2026-04-17 20:39:16
Piper Sandler has reduced its price target for Merit Medical Systems (NASDAQ: MMSI) from $106 to $96, while maintaining an Overweight rating. This adjustment follows an update to their revenue model to reflect Merit Medical's new "Foundational" and "Therapeutic" reporting structure and incorporates the recent $140 million acquisition of View Point Medical. Despite the lowered price target, InvestingPro analysis suggests MMSI remains undervalued.
2026-04-17 19:08:03
Piper Sandler has reiterated an Overweight rating for Merit Medical Systems (MMSI) but adjusted its price target down to $96.00 from $106.00. Despite this revision, the company is considered undervalued by 26.1% according to GuruFocus's GF Value™ and holds a strong GF Score™ of 85/100, indicating robust fundamentals, particularly in growth and profitability. The article suggests MMSI could be an attractive investment opportunity given its solid financial health and growth potential.
2026-04-17 14:40:03
Piper Sandler has reduced its price target on Merit Medical Systems (NASDAQ: MMSI) to $96 from $106, while maintaining an Overweight rating. This adjustment follows an update to their revenue model to reflect Merit Medical's new reporting structure and the recent $140 million acquisition of View Point Medical. Despite the cut in price target and lowered EPS estimates for 2026 and 2027, the firm's core growth rates for the company remain largely unchanged, and Merit Medical is considered undervalued.
2026-04-17 13:40:03
BTIG analyst Sam Eiber maintained a Buy rating on Merit Medical Systems, Inc. (MMSI) but lowered the price target to $100 from $107 due to model revisions related to CMS's proposed FY27 inpatient payment framework. Separately, Merit Medical Systems acquired View Point Medical, Inc. for approximately $140 million, expanding its oncology portfolio. This acquisition is expected to modestly contribute to revenue in 2026, with stronger financial benefits projected for 2027.
2026-04-16 20:39:15
Merit Medical Systems has initiated a worldwide Class I recall of two hemodialysis catheter product lines, DuraMax and CentrosFLO, due to a design defect posing significant patient safety risks. This recall affects over 57,000 units and prompts investors to reassess the company's growth narrative, quality controls, and potential financial and legal impacts. The company's management of this recall will be crucial for maintaining trust with regulators and healthcare providers and for its stock performance, which has seen declines year-to-date and over the past year.
